Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Noxopharm Ltd. ( (AU:NOX) ) has shared an announcement.
Noxopharm Ltd., a biotechnology company, has announced the issuance of 2,600,000 convertible notes and 520,000 unlisted options to professional, sophisticated, or exempt investors, generating $2.6 million before costs. This move is aimed at enhancing its capital structure, with the potential to significantly increase the number of shares if the convertible notes are converted, which may lead to dilution of existing shareholders’ stakes. The issued convertible notes carry a 12% annual interest and can be converted into shares, thereby impacting the company’s financial position and capital structure.
More about Noxopharm Ltd.
YTD Price Performance: -1.11%
Average Trading Volume: 170,351
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$26.01M
For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.
